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Abstract Transfer of the SV40 large-T (LT) oncogene into 
isolated human and murine intestinal epithelial cells induced 
alterations of the ultrastructural organization and polarization of 
the resulting immortalized cell lines. We now demonstrate that 
the functional expression of the SV40 LT antigen in Caco-2 cells 
did not alter phenotypic markers of differentiation, including 
expression of villin, sucrase-isomaltase, brush border and dome 
formation. As compared to parental cells, the transfected Caco-
2LT9 cells exhibited similar growth curves and no invasive 
properties in vitro. The major oncogenic function of the SV40 LT 
antigen in transfected Caco-2 cells is associated with reduced 
latency times necessary for the manifestation of tumors in 
athymic nude mice. The Caco-2 cell line contained deleted and 
mutant p53 alleles (stop codon in position 204) and has no 
detectable truncated p53 protein by Western blot. Molecular 
complexes between the SV40 LT antigen and the retinoblastoma-
related proteins pRbl and Rb2 were clearly identified at the 
different phases of the growth curve. When compared to normal 
human colonic crypts, Caco-2 cell differentiation is related to 
partial redistribution of pRbl into hypophosphorylated, anti-
proliferative forms. The pRb2 protein is found elevated in a 
subset of human colorectal tumors and their corresponding liver 
metastases. We conclude that: (1) Caco-2 cells exert a dominant 
control against the oncogenic functions of the LT antigen; (2) 
loss of p53 function is not restrictive for the establishment of 
polarity and differentiation of the enterocyte lineage; (3) the 
levels and phosphorylation status of the Rbl and Rb2 proteins 
may play important roles in the proliferation and differentiation 
of normal and neoplastic human colonic mucosa. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
The cellular and molecular mechanisms of tumor progres-
sion involve point mutations, chromosomal rearrangements 
and loss of tumor-suppressor genes [1-4]. Transfer of genetic 
elements derived from mammalian DNA tumor viruses is 
often associated with the development of cellular prolifera-
tion, immortalization and transformation of mesenchymal 
and epithelial cells [5,6]. Genetic and biochemical studies 
have shown that the SV40 large T antigen (SV40 LT) is com-
posed of several functional domains interacting with different 
cellular targets in the cytoplasm and nucleus [5-7]. For exam-
*Corresponding author. Fax: (33) 1-49284694. 
pie, the SV40 LT antigen is known to form complexes with the 
tumor-suppressor gene products p53 and pl05Rbl, and to 
antagonize their functions regarding proliferation, differentia-
tion and senescence. In this connection, we have previously 
demonstrated that the viral oncogenes large T of SV40 and 
polyoma, the early region El A of adeno virus 2 extend the life 
span of primary epithelial cells isolated from the gastrointes-
tinal tract [8-13]. Transfection of gastric and intestinal epithe-
lial cells by plasmid vectors and retroviruses carrying the 
SV40LT oncogene has resulted in the establishment of per-
manent cell lines at various stages of the neoplastic transfor-
mation. In addition, we have investigated the consequences of 
the cellular immortalization and transformation upon some 
differentiation criteria, including cell polarity and ultrastruc-
tural characterization, expression of specific markers of the 
human and murine digestive epithelia. We have found that 
the introduction and expression of SV40 LT in primary gastric 
and intestinal epithelial cells is correlated with altered differ-
entiation of the corresponding cell lines. 
In the present study, we examined the effects of SV40 LT on 
the growth and differentiation of the human colonic adeno-
carcinoma Caco-2 cells. This cell line provides an appropriate 
model to study the neoplastic progression and differentiation 
in intestine since Caco-2 cells are poorly tumorigenic in nude 
mice and grow as typical enterocytes in culture [14]. The sta-
tus of the tumor suppressor proteins p53, Rbl and Rb2 was 
also characterized in the parental and SV40 LT-transfected 
Caco-2 cell lines. 
2. Materials and methods 
2.1. Materials 
[o>32P]dCTP (3000 Ci/mmol) was purchased from Amersham Corp. 
(Les Ullis, France). The anti-Rbl antibodies C36 (mouse mAb for 
immunoprecipitations) and C15 (rabbit pAb for Western blots) were 
from Santa Cruz Biotechnology (Tebu, Le Perray and Yvelines, 
France). The affinity-purified rabbit anti-Rb2 pAb was directed 
against the C-terminal region of the protein. The mouse mAb to 
SV40LT antigen (Pab 101), the p53 mouse mAb DO-1 specific of 
the amino terminal region 37-45 of the p53 protein, and the mouse 
mAb 421 specific of the carboxyl terminal region of p53 (371-380 C-
terminal region) were from Oncogene Science (Paris, France). The 
mouse mAb PAb762 directed against the Py antigens was kindly pro-
vided by Dr. S. Dilworth (Hammersmith Hospital, London, UK). The 
expression vector pMSPE encoding the SV40LT antigen and neore-
sistance was a generous gift from Dr. M. Schuermann (IMT, Philipps-
Universitat Marburg D-3550, Germany). All other chemicals were of 
analytical grade. 
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2.2. Cell culture and transfection 
The human colonic adenocarcinoma Caco-2 and HT-29 cell lines 
were obtained from Dr. A. Zweibaum (INSERM U 178, Villejuif, 
France). The CFI-3 cell line was established after transfection of pri-
mary human intestinal cells by the SV40LT oncogene [9], In standard 
conditions, all three cell lines were grown at 37°C in Dulbecco's 
modified Eagle medium (DMEM, from Gibco BRL, Grand Island, 
NY) supplemented with 8 mM L-glutamine, antibiotics, and 15% fetal 
calf serum (Deutscher, France) in an atmosphere of 95% air/5% CO2. 
Cells were passaged weekly, using 0.005% (w/v) trypsin, 0.02% (w/v) 
EDTA in a 1:10 split ratio. The human colonic adenomatous cell line 
PC AA/C1 cell line [15], designated as the PC cells throughout this 
study, and their polyoma large T-transfected counterparts PCPy/csrc 
cells, were cultured in the same culture medium supplemented with 0.2 
U/ml insulin and 1 (ig/ml hydrocortisone. 
Caco-2 cells at passage 67 were harvested and washed in a solution 
containing 10 mM Na2HP04/NaH2P04, 250 mM sucrose and 1 mM 
MgCl2 (pH 7.45). About 107 Caco-2 cells were incubated for 10 min 
at 4°C in 1 ml of the same buffer, in the presence of 10 mg of the 
pMSPE vector recombined with the origin-defective mutant of SV40. 
The Caco-2 cells were transiently permeabilized by a BioRad appara-
tus (675 V/cm, 25 uFd). Transfected cells were allowed to grow for 
2 days, after which the selection medium containing 1 mg/ml of the 
neomycin analogue G418 was added to the cultures. Dishes were then 
left for 2 weeks with weekly selection medium change. The surviving 
colonies were isolated using cloning cylinders, amplified and analyzed 
for the expression of the viral transgene. The different clones of Caco-
2 cells isolated after transfer of the SV40 LT and neogenes were des-
ignated by the suffix (-LT). 
2.3. Tissue samples 
Tissue samples obtained from patients at surgery (Centre de Chi-
rurgie Digestive, Service du Pr. Pare, Hopital Saint-Antoine) were 
immediately frozen in liquid nitrogen. Specimen from non-necrotic 
malignant tissue and adjacent non-neoplastic mucosa were dissected, 
snap-frozen in liquid nitrogen and stored at —80°C until protein ex-
traction. The specimens included adenocarcinomas of Dukes' stages 
B, C and D, and liver metastasis. 
2.4. RNA isolation and Northern blot 
Total RNAs were isolated by guanidinium isothiocyanate extrac-
tion and cesium chloride density gradient ultracentrifugation. After 
denaturation, RNA samples underwent electrophoresis in 1% agarose, 
2.2 M formaldehyde gels, were transferred onto Hybond N+ nylon 
membranes (Amersham, UK), and hybridized with the 32P-labeled 
probe (Megaprime, Amersham). The membranes were then washed 
twice for 15 min at room temperature in 2XSSC, 0.1% SDS 
(2XSSC is 0.3 M NaCl, 30 mM sodium citrate, pH 7.0) and incu-
bated for 60 min at 42°C in 0.1 XSSC, 0.1% SDS. Autoradiographs 
were performed at — 70°C using Kodak X-Omat AR films (Rochester, 
NY) and a Chronex Quanta III intensifying screen (Dupont). The 
relative abundance of RNA per lane was judged to be similar by 
comparing the ethidium bromide or methylene blue staining of the 
ribosomal bands. 
The SV40 LT probe consisted of the 5.2-kb BamHl fragment of the 
pSV40 plasmid containing the viral sequence without the origin of its 
replication [9]. The RB probe was the human cDNA isolated from the 
pCMV-HRB plasmid, a generous gift from Dr. R. Weinberg (Cam-
bridge, MA). The PCV 108 cosmid containing a Clal-EcoRI fragment 
of the c-myc gene (third exon) was used as a probe [16]. The villin 
probe was the human cDNA isolated from the plasmid pSP64V19 
after digestion by BamHl and Sail (Dr. E. Pringault, Paris, France). 
2.5. P53 gene analysis 
Since the vast majority of the mutations in the P53 gene are located 
in exons 5-9, this region was analyzed by PCR and direct sequencing 
of the amplified products. Genomic DNA (150 ng) was amplified in 
100 ul of reaction mixture containing 0.5 uM of each primer, 0.1 mM 
of each dNTP and 5 units of Taq polymerase (Perkin-Elmer Cetus), in 
a buffer containing 10 mM Tris-HCl (pH 8.3), 50 mM potassium 
chloride, 2.5 mM magnesium chloride and 0.001% gelatin. 
Primers were synthesized by the phosphoramidite method with a 
391 DNA synthesizer (Applied Biosystems). Names and sequences 
were as follows: 
sense 
antisense 
sense 
antisense 
sense 
antisense 
sense 
antisense 
sense 
antisense 
5'TTCAACTCTGTCTCCTTCCT 
5'CAGCCCTGTCGTCTCTCCAG 
5'GCCTCTGATTCCTCACTGAT 
5'TTAACCCCTCCTCCCAGAGA 
5'GTAAAGCTTGTTGGCTCTGACTG-
TACCACC 
5'ACAAAGCTTCCTGGAGTCTTC-
CAGTGTGAT 
5'TTCCTTACTGCCTCTTGCTT 
5'AGGCATAACTGCACCCTTGG 
5'TTGCCTCTTTCCTAGCACTG 
5'CCCAAGACTTAGTACCTGAA 
Reactions were performed for 35 cycles comprising a denaturation 
step (30 s at 94°C), followed by primer annealing (15 s, 55°C) and 
elongation for 30 s at 72°C. Double-strand amplified DNA was pu-
rified from the remaining primers by centrifugation through Centri-
con-100 columns (Amicon), according to the manufacturer's instruc-
tions. Amplification products were controlled and quantified by gel 
electrophoresis on 2% agarose gels. The PCR products (100 ng am-
plimeres) were subjected to a dideoxy-termination sequencing proce-
dure using the Prism M reaction Kit, according to the protocol sup-
plied by Applied Biosystem. Taq sequencing reactions were carried 
out for 25 cycles in a thermal cycler Beckman 9600, for 30 s at 96°C 
and 4 min at 60°C. Extended fragments were purified from uncorpo-
rated nucleotides and primers through quick spin columns (Boeh-
ringer). The reaction products were dried, resuspended in 4 uj of 
deionized formamide containing 50 mM EDTA (pH 8), heated to 
90°C for 2 min, transferred to ice and loaded on a 6% polyacrylamide, 
8 M urea gel. Gels were run for 12 h on ABI Model 373 A automated 
DNA sequencer. The chain reactions were performed on genomic 
DNA samples prepared from cultured Caco-2 cells at three different 
passages. 
Reverse transcription-polymerase chain reaction (RT-PCR) was 
carried out on total RNA (1 jig) extracted from cultured Caco-2 
and HT-29 cells or human tissue resections for colorectal cancer. 
RNA was reverse transcribed in 20 jxl of final volume containing 
500 itM dNTP, 10 mM DTT, 0.5 U/ul RNasin (Promega Corpora-
tion), 5 u\M random hexamers and 10 (ig/ml reverse transcriptase 
(Gibco BRL, Bethesda, MD). The RT reactions were terminated by 
heating at 96°C for 5 min and quick-chilled on ice. The corresponding 
cDNA (5 lil) was added to 25 |il of the PCR mixture containing 10 
mM Tris-HCl (pH 8.3), 50 mM MgCl2, 0.001% gelatin, 0.05 U Taq 
DNA polymerase (Beckman, USA) and 0.5 mM of two sets of pri-
mers corresponding to p53 and |3-actin sequences. The PCR reaction 
was performed in a Perkin-Elmer 9600 thermocycler (Cetus). Each 
cycle consisted of 15 s denaturation at 94°C, 15 s annealing at 58°C 
and 30 s extension at 72°C. Negative controls were done using RNA 
samples processed in the absence of reverse transcriptase. PCR prod-
ucts (10 uf) were then electrophoresed in 2% agarose gels. Fluores-
cence intensity of the PCR products was automatically measured us-
ing the Genescan Software in the ABI model 373 spectrofluorimeter 
(Applied Biosystem). The optimal number of PCR reactions to allow 
quantification of the expression of the p53 and $-actin genes was 26 
cycles. The amount of the p53 mRNA signal was expressed as arbi-
trary densitometric units (ALT) and normalized for the level of mRNA 
encoding P-actin. 
2.6. Western blot, immunoprecipitation, and immunofluorescence 
The parental and SV40 LT-transfected Caco-2 cells (5X106 cells) 
were solubilized in 1 ml of lysis buffer containing 50 mM Tris-HCl 
(pH 8), 120 mM NaCl, 0.5% NP40 (v/v) and aprotinin (10 itg/ml). 
Denaturation was performed for 2 min in the sample buffer contain-
ing 50 mM Tris-HCl (pH 6.5), 1% SDS, 10% glycerol, 20% p-mercap-
toethanol and 0.002 bromophenol blue. Samples were adjusted to a 
protein concentration of 100 fig/well and submitted to electrophoresis 
in a 7% polyacrylamide slab gel. Proteins were transferred onto Hy-
bond-C-Extra nitrocellulose membranes (Amersham) at 0.8 mA/cm2 
for 1 h, using a Semidry transfect unit Multiphor II (LKB Bromma, 
Sweden). The membranes were briefly stained with Ponceau S to as-
sess the equality of protein transfer and blocked overnight with 5% 
skimmed milk powder in Tris-saline buffer, containing 10 mM Tris-
HCl, 150 mM NaCl (pH 8). Membranes were then incubated for 1 h 
at 22°C, with a 1:100 dilution of either the mouse anti-SV40 LT anti-
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gen mAb (Pab 101), the Rbl pAb C15 or the p53 mAbs against the 
N- or C-terminal regions of the protein. 
The immunoblots were then washed in Tris-saline buffer containing 
0.05% Tween-20, incubated for 1 h at 22°C with a 1:1000 dilution of 
the corresponding secondary polyclonal sheep antibodies conjugated 
with horse radish peroxidase, and probed using the enhanced chem-
iluminescence system (ECL, Amersham, UK). 
For immunoprecipitation of the pRbl and Rb2 proteins, human 
intestinal cells in culture were homogenized and lysed in ice-cold buf-
fer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 20 mM 
EDTA, 0.5% NP40, 1 mM sodium orthovanadate, 50 mM NaF, 45 
|Xg/ml aprotinin and 100 u.g/ml phenylmethylsulfonylfluoride. Cell ly-
sates were cleared by centrifugation at 15000Xg for 10 min and the 
supernatant containing 2 mg cell protein was incubated for 1 h at 4°C 
with either the C36 RBI (1 ug protein antibody) or the pRb2 anti-
body (5 ul) directed against the COOH-terminus of the protein. Then, 
40 ml of protein G-Sepharose was added and the immunoprecipita-
tion was performed for 1 h at 4°C. The immunoprecipitates were 
washed 3 times in 1 ml of the same buffer, resuspended in sample 
buffer and boiled. Electrophoresis was performed in the conditions 
described above. 
Intestinal cells grown on Labtek (PolyLabo, France) were fixed for 
10 min at 4°C in a 2:1 mixture of methanol/acetone. This material 
was incubated for 90 min with a 1:10 dilution of the primary mAb 
against the SV40LT antigen and then with the anti-mouse IgG 
coupled to fluorescein as second antibody (Silenus, France). Prepara-
tions were observed with a microscope equipped with epifiuorescence 
optics (Leitz). 
2.7. Cell proliferation and tumorigenicity 
Parental and transfected Caco-2 cells were seeded at the initial 
density of 50000-100000 cells per 60 mm Falcon dishes in the stand-
ard culture medium containing either 15, 5 or 1% fetal calf serum. In 
some experiments, cell proliferation was measured in the absence of 
serum or glutamine. The culture medium was renewed every 48 h and 
the cell count was performed daily, using a Coulter Counter (Coul-
tronics, Luton, UK). 
About 107 Caco-2 cells (parental or transfected cell lines) were 
injected subcutaneously into athymic nude mice, 4—6 weeks old. All 
animal were monitored weekly for the presence and size of the tumors 
over a period of 3 months. The latent period to tumor development 
was defined as the period until a hard palpable and measurable tumor 
appeared. Tumor growth was evaluated by 3-dimensional calliper rule 
measurements of length (L), width (W) and height (H). Tumor vol-
ume was calculated by the formula: A = 4/3>nXLXWXH. Tumors 
were removed when they reached about 8 mm in diameter to minimize 
discomfort to the mice. 
2.8. In vitro invasion assay 
The invasive potential of the parental and SV40 LT-transfected 
Caco-2 cells was investigated in vitro, in type I collagen gel and chick 
heart fragment invasion assay, as previously described [17,18]. The 
invasion index was expressed as the percentage of cells invading the 
gel over the total number of cells. An invasion index higher than 10% 
designated highly invasive cells. 
2.9. Ultrastructural analysis and sucrose activity 
Caco-2 cells were cultured for 10 days after the acquisition of con-
fluence, and fixed for 2 h at room temperature in Cacodylate buffer 
(pH 7.2) containing 2% formaldehyde, 4% glutaraldehyde and 0.06% 
picric acid. After postfixation in osmium tetroxide, the samples were 
processed for electron microscopy, as previously described [18]. Su-
crase activity was measured according to Dahlqvist, using sucrose as 
substrate [18], 
3. Results 
3.1. Transfection of Caco-2 cells by the SV40LT oncogene 
Parental Caco-2 cells at passage 67 underwent electroper-
meabilization and were transfected by the pMSPE expression 
vector encoding the SV40LT antigen and neoresistance. We 
observed that this expression vector pMSPE is efficient to 
immortalize human thymic epithelial cells in primary culture 
Fig. 1. SV40LT oncogene expression in SV40 LT-transfected Caco-2 
cells. A: Northern blot analysis of the SV40LT transcript. Total 
RNA samples were extracted from the parental Caco-2 cell line and 
nine different clones obtained after selection of the transfected cells 
using 1 mg/ml G418. The G418-resistant colonies were designated 
Caco-2 LT1 to -LT9. B: Western blot analysis of the SV40LT onco-
protein. Cellular extracts were prepared from parental and trans-
fected Caco-2LT8 and -LT9 cells, after selection by G418. T Ag: 
SV40LT antigen. 
(C.G., unpublished observations). The Caco-2 cells expressing 
the transgene sequences were selected in culture medium con-
taining 1 mg/ml of the neomycin analogue G418. The non-
transfected parental cell line treated with 1 mg/ml G418 did 
not survive at this drug concentration. After selection by 
G418 for 2 weeks, nine clones were obtained and subsequently 
analyzed for the accumulation of the SV40LT transcripts 
(Fig. 1A). Northern blot analysis revealed that the LT2 and 
LT9 clones exhibited high accumulation of the SV40LT 
mRNA identified as a main band of 2.5 kb. In contrast, the 
LT8 subclone showed lower abundance of the SV40 LT tran-
scripts, while no hybridization occurred using the RNA ex-
tracted from the LT5- and LT6-resistant colonies (data not 
shown). The persistence of the transgene expression was 
checked in Caco-2 LT9 cells at passages 71 and 81. The 
Caco-2 LT9 clone expressed moderately higher levels of T 
antigen (T Ag) than the -LT8 clone (Fig. IB). 
Approximately 80% of the Caco-2 LT9 cells expressed the 
SV40LT antigen within their nuclei by immunofiuorescent 
staining. This expression remained stable over passages in 
culture (data not shown). Similar nuclear staining was ob-
served in the SV40 LT-immortalized rat intestinal cell line 
SLC-44 [8]. 
3.2. Proliferation, tumorigenicity and invasiveness 
Growth of parental and SV40 LT-transfected Caco-2 cells 
was measured by seeding equal numbers of cells (0.5 to 1 X 10° 
cells) into 60 mm Petri dishes. Cell number was determined at 
different times, during the exponential phase of growth and 
after the acquisition of confluence. 
The growth curves of the Caco-2 and -LT9 cell lines were 
similarly affected by decreasing the serum concentrations from 
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Fig. 2. Tumorigenicity of the parental and Caco-2LT9 cells. Nude 
mice were inoculated subcutaneously with 107 cells. Each point is 
the mean of 20 measurements representative of four separate experi-
ments. Caco-2 (o) and Caco-2 LT9 cells (•). 
15% to 1% in the culture medium. The parental and trans-
fected Caco-2 cells also grew at similar rates in the absence of 
serum or glutamine, and were propagated for 11-15 passages 
under these restrictive culture conditions (data not shown). 
Glutamine was described as an essential nutriment for the 
growth of intestinal epithelial cells [21-23]. Accordingly, the 
doubling time increased from 32 h in Caco-2 and -LT9 cells 
cultured in the presence of serum, to 49 h in Caco-2 cells 
deprived of serum or glutamine. 
Following the introduction into nude mice of 107 cells, the 
parental Caco-2 cell line grew slowly to produce significant 
tumor formations by 8-11 weeks following injection (Fig. 2). 
In contrast, expression of the SV40 LT antigen in the Caco-
2LT9 cell line leads to shorter latency times so that tumors 
were observed by 4-8 weeks with similar growth rates once 
initiated. 
The invasive properties of the parental and SV40 LT-trans-
fected Caco-2 cells were evaluated by measuring cellular in-
vasion of type I collagen gel and embryonic chick heart frag-
ments. As shown in Fig. 3, expression of SV40 LT in Caco-2 
cells is not associated with the acquisition of invasiveness in 
the collagen gels assay. Similarly, Caco-2 and -LT9 cells did 
not invade into the chick heart (data not shown). They 
formed epithelioid monolayers and multilayers surrounding 
the heart fragments. Fibroblastic transformation of the car-
diac muscle was frequently observed at the vicinity of the 
Caco-2 cells. 
3.3. Morphological and functional differentiation 
Post-confluent cultures of Caco-2 cells were characterized 
by the progressive emergence of domes, as previously de-
scribed [14]. Expression of the SV40LT antigen in Caco-
2LT8 and -LT9 cells was also associated with dome forma-
tion with similar size and density. 
Parental and transfected Caco-2 cells cultured in the stand-
ard culture medium had the characteristic ultrastructural mor-
phology of differentiated enterocytes. They formed a contin-
uous monolayer of polarized cells displaying an apical surface 
covered with abundant microvilli (data not shown). Central 
actin microfilaments in the microvillus core extended deeply 
into the cytoplasm. Apical junctional complexes, including 
tight junctions and desmosomes have often been observed in 
both cell lines. Sucrase-isomaltase activity was similar in 
Caco-2 and Caco-2 LT9 cell line during the exponential phase 
of growth and confluent monolayers (data not shown). This 
activity gradually increased 10 days after confluence and this 
evolution was not prevented in Caco-2 cells transfected by the 
Fig. 3. Invasive potential of the parental and Caco-2LT9 cells, a: The invasion index was expressed as the percentage of cells invading the gel 
over the total number of cells, b: Maximum depth of cell penetration into the gel. MCF-7/AZ cells are non-invasive variants selected from the 
parental human mammary cell line MCF-7. DHD-FIB cells belong to a myofibroblast cell line derived from a chemically induced rat colon 
cancer. These two cell lines represent non-invasive and invasive controls in this assay. C2 and C2LT9: Caco-2 and Caco-2 LT9 cells. 
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Fig. 4. Expression and phosphorylation pattern of pRbl during enterocyte differentiation of parental and Caco-2 LT9 cells. The amount and 
the phosphorylation status of pRbl-immunoreactivity was analysed by Western blotting in parental Caco-2 cells (C2) and Caco-2LT9 cells 
(C2LT9) cultured in the presence of SVF (15%) or in serum-free medium (0%). Protein extracts were harvested in Caco-2 cells during the expo-
nential phase of growth (E), at confluence (C) and in 10 days post-confluent monolayers (10). The five bands shown represent forms of pRbl 
with different degrees of phosphorylation. Data are representative of three other experiments. 
SV40LT oncogene. Similarly, the two specific transcripts of 
the villin gene (2.7 and 3.5 kb) were equally accumulated in 
the two cell lines during the three phases of the cell culture 
considered (data not shown). 
3.4. Phosphorylation pattern of pRbl and enterocyte 
differentiation 
The accumulation and the pattern of phosphorylation of 
pRbl was analyzed in Caco-2 and -LT9 cells at various stages 
of growth and differentiation (Fig. 4). Five different phos-
phorylated forms of pRbl protein were clearly detected as 
closely spaced bands at approximately 105-110 kDa. In stand-
ard culture conditions (15% SVF) or in the absence of SVF 
(0%), the majority of pRbl was hyperphosphorylated during 
the exponential growth and at confluence. In contrast, pRbl 
exhibits a hypophosphorylated pattern in terminally differen-
tiated enterocytes obtained 10 days after confluence. In com-
parison, only one hypophosphorylated form of pRbl could be 
detected in freshly isolated human colonic crypts. Expression 
of the SV40 LT antigen in Caco-2 LT9 cells resulted in accu-
mulation and persistence of two hyperphosphorylated forms 
in bands 2 and 3. 
3.5. pRbl/SV40 LT interactions and p53 status 
As shown in Fig. 5, the Rbl/pl05 protein interacts with the 
large T antigen in transfected Caco-2 LT9 cells, as demon-
strated by immunoprecipitation of pRbl with the pAb C36 
and subsequent revelation of the SV40 LT antigen by Western 
blot. The pRbl-LT antigen complex is clearly identified in 
transfected cells harvested during the exponential phase of 
growth, at confluence or in 10 days post-confluent mono-
layers. 
In contrast, Western immunoblot analysis indicated that the 
Caco-2 cell extracts do not contain detectable levels of p53 
protein (Fig. 5). The same situation was observed in SLC-44 
cells, freshly isolated human colonic crypts, and K-562 cells 
which have no p53 mRNA. In contrast, human colonic HT-29 
cells accumulated high levels of immunoreactive p53 protein 
by Western blot, using the mAbs DO-1 and 421 that recognize 
respectively the amino-terminal transactivation domain of p53 
(N-t) and the carboxy-terminal region (C-t). This cell line 
harbours a G/A (Arg>His) mutation in codon 273 of the 
p53 gene [19]. Since the wild-type p53 protein has a short 
half-life of few minutes and is not detectable immunochemi-
Fig. 5. Detection of the pRbl-SV40LT antigen complexes. A: Im-
munoblot analysis of the pRbl and SV40LT in pRbl immunopreci-
pitates prepared from parental (C2) and SV40 LT-transfected Caco-
2 cells (C2LT9). pRb was first immunoprecipitated using the 
C36 pAb and revealed by Western blot using the rnAb C15. The ni-
trocellulose membrane was then stripped of bound antibodies and 
reprobed with the mouse mAb to SV40 LT antigen (T Ag). E: ex-
ponential phase of growth; C: confluent monolayers; 10: 10 days 
post-confluent Caco-2 cells. B: Western blot analysis of the p53 
protein in parental (C2) and transfected Caco-2 LT9 cells (C2LT9); 
HT-29 human colonic cells as a positive control, K562 human mye-
logenous leukemia cells as a negative control, SLC-44 cells and hu-
man colonic epithelial cells (HC). The p53 protein was revealed us-
ing the mouse mAb DO-1 (N-terminal region specific: N-t) or the 
mouse mAb 421 (C-terminal region specific: C-t). 
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Fig. 6. Analysis of p53 gene expression. The PCR products obtained from reverse-transcribed Caco-2 RNA were compared to those from HT-
29 RNA, and two paired samples from human tissue resections for colon cancer (Nl/Tl and N2/T2, N: non-tumoral mucosa; T: adenocarci-
noma). Internal positive and negative controls of p53 RNA (C+: normal size p53 band from a colorectal carcinoma with increased accumula-
tion of p53 transcript; C-: non-tumoral colonic mucosa with no detectable p53 gene expression). The arrows indicate the migration positions 
of amplified RT-PCR products from p53 and $-actin genes. First lane: molecular weight markers. 
cally in non-tumoral colonic epithelial cells and stroma adja-
cent to sporadic colonic cancers [19], the status of the p53 
gene and its transcripts was therefore investigated in Caco-2 
cells. 
Direct sequencing of the PCR products corresponding to 
exons 5-9 of the p53 gene revealed the presence of a stop 
codon in position 204 from exon 6. This cell line has lost 
the other allele of the p53 gene. Fig. 6 shows the expression 
of the p53 gene in Caco-2 cells. In comparative experiments, 
RT-PCR was also performed in the p53-positive HT-29 cell 
line and two human colon tumor samples. Expression was 
high in HT-29 cells (1.2 AU), lower in Caco-2 cells (0.35-
0.39 AU) and much weaker or absent in a non-tumoral co-
lonic mucosa, as compared to its corresponding adjacent pri-
mary tumor (0.03 and 0.36 AU in lanes Nl and Tl , respec-
tively). In contrast, the p53 transcripts were undetectable by 
RT-PCR in the other paired samples. 
3.6. pRb2 status and interaction with SV40LT 
We next investigated the expression of the retinoblastoma-
related phosphoprotein Rb2/pl30, a negative regulator of pro-
liferation and cell cycle progression [20], in SV40 LT-trans-
fected human intestinal cell lines Caco-2 LT9 and CFI-3 [9], 
and parental or polyoma LT-transfected PC colonic epithelial 
cells (Fig. 7). By Western blot analysis, using the affinity-pu-
rified pAb directed against the spacer region of pRb2, we 
detected two autoradiographic bands at the expected molec-
ular mass between 130 and 138 kDa, corresponding to differ-
ent degrees of phosphorylation. In immunoprecipitates pre-
pared from the SV40 LT-transfected CFI-3 and Caco-2 LT9 
cells, we identified the 90 kDa antigen, indicating stable asso-
ciation between the viral oncoprotein and pRb2. In contrast, 
the polyoma LT antigen was not detected in pRb2 immuno-
precipitates prepared from the PCPy/csrc cells transfected by 
the Polyoma early region (Fig. 7). 
3.7. Expression of pRb2 in normal and transformed human 
colonic mucosa 
Accumulation of Rb2/pl30 protein was investigated in nor-
mal human colonic epithelial crypts and during the neoplastic 
progression of the human colonic mucosa. As shown in Fig. 8, 
pRb was undetectable in normal human colonic crypts (HC). 
The amount of pRb2 increased in tissue extracts prepared 
from Dukes' stages B1/B2, C2 or D, and their adjacent non-
tumoral mucosa. The Rb2 protein was also detected in liver 
metastases of colonic cancers (M), but not in adjacent tissue 
(L). 
4. Discussion 
The gastrointestinal epithelia undergo a rapid and continu-
ous renewal of their cell lineages from primitive stem cells 
localized in the gastric isthmus and intestinal crypts. In adults, 
these progenitors are mainly undifferentiated or committed as 
intermediary precursors of the epithelia. During fetal life in 
rats, proliferation and DNA synthesis is not restricted to this 
proliferating zone in the intestine and occurs along the emerg-
ing villi structures and stratified epithelium. In these condi-
tions, oncogene-mediated immortalization of fetal and neona-
tal intestinal epithelial cells by the SV40LT oncogene was 
previously associated with the emergence of poorly differenti-
ated cell lines, with retention of some specific determinants of 
the digestive epithelia. This situation is also observed in condi-
tionally immortalized intestinal epithelial cells from transgenic 
mice using the temperature-sensitive SV40LT antigen under 
the control of an interferon 7-inducible H-2Kb promoter ele-
ment directing the expression of the transgene in every cell 
[24]. These transgenic intestinal H-2Kb-tsA58 cells were found 
to be morphologically primitive with no morphological evi-
dence of differentiation, and retained some specific biochem-
ical markers of the normal digestive epithelia. Introduction of 
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Fig. 7. pRb2 status and detection of the pRb2-SV40LT complex. A: Immunoblot analysis of pRb2 in total cellular extracts (left) or in Rb2-im-
munoprecipitates (right). B: Detection of the SV40LT antigen by Western blot (left), and pRb2-SV40LT complexes in pRb2 immunoprecipi-
tates prepared from the SV40 LT-transfected Caco-2LT9 and CFI-3 cells (right). C: Immunoblot analysis of PyLT in total cellular extracts 
(left) or in pRb2-immunoprecipitates prepared from the parental or PyLT-transfected PC/AA cells. 
thermolabile SV40 LT antigen under the SV40 early promoter 
in primary fetal intestinal epithelial cells also resulted in the 
expression of epithelial markers and induction of a more dif-
ferentiated phenotype at the restrictive temperature [25]. An-
other elegant approach was to target the expression of 
SV40LT in intestinal epithelial cells using tissue-specific reg-
ulatory sequences of the mouse intestinal FABP fatty acid 
protein gene [26,27]. In this transgenic I-FABP/SV40 LT anti-
gen model, crypt-associated cells of the small intestine do not 
contain detectable levels of LT antigen since transgene expres-
sion is first detectable in enterocytes as they exit the crypts. 
The accumulation of the SV40 LT antigen in enterocytes per-
sisted during migration along the crypt-villus axis, with no 
apparent effect on enterocytic differentiation markers, such 
as FABP, alkaline phosphatase, and morphology by light mi-
croscopic studies. However, there was no information on the 
ultrastructural organization and polarization of the LT anti-
gen-expressing epithelial cells of the villi. When isolated from 
the I-FABP/SV40 LT transgenic intestine, epithelial cells did 
not produce any tumor in nude mice. Attempts to establish a 
permanent cell line from the same material were unsuccessful 
(J.I. Gordon, personal communication). In vivo, this trans-
genic intestine showed very mild dysplasia illustrated by bi-
furcated villi structures emerging from the crypts [27]. Estab-
lishment of transgenic animals using intestine-specific 
promoters already expressed in the proliferating crypt cells, 
such as the lactase-phlorizin hydrolase or OCT1 type trans-
porters [28,29], or in the proliferative part of the colonic 
crypts, such as the MSH2 gene [30], will allow precise evalua-
tion of the consequences of SV40 LT expression on the pro-
liferation and differentiation of the immature stem cells. 
In this study, we have shown that expression of the 
SV40LT oncogene in the human Caco-2 cell line resulted in 
minor changes in cell proliferation, tumor growth and differ-
entiation, as judged by phase-contrast microscopy, ultrastruc-
tural organization or polarization, and expression of digestive 
enzymes. In contrast, we have previously shown that trans-
formation of Caco-2 cells after transfer of the ras and polyoma 
middle-T oncogenes not only promoted cell proliferation and 
tumor growth but also impaired enterocytic differentiation 
[18,31,32]. Our data therefore support the hypothesis that ter-
minal differentiation of the Caco-2 enterocytes is compatible 
with the expression of SV40 LT. One potential explanation for 
these results invokes the possibility that SV40LTis a repress-
er of the differentiation program when this oncogene is ex-
pressed in undifferentiated proliferating intestinal epithelial 
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Fig. 8. pRb2 status in human colonic tumors. Protein samples (100 ug) were analyzed by Western blotting using the pAb against the C-termi-
nal region of pRb2. Normal human colonic crypts: HC; Dukes' stages Bl, B2, C2 and D; liver metastasis: M. The corresponding adjacent 
non-neoplastic tissue (colonic mucosa or liver) was analyzed for each paired resection from the same patient. 
cells, and has permissive action in digestive cells that are al-
ready differentiated. Alternatively, it is also possible that the 
Caco-2 cell genotype exerts a dominant negative effect on the 
function of the SV40LT oncogene. 
In favor of this hypothesis, we first demonstrate here that 
the p53 gene in Caco-2 cells has deleted and mutated alleles 
and no detectable accumulation of the corresponding protein. 
The stop codon in position 204 of the p53 gene argues for a 
defective p53 protein at two levels. This putative truncated 
p53 protein in Caco-2 cells eliminates the possibility of the 
interactions with DNA binding sites or SV40LT antigen in 
the domains located in the central part of the molecule (amino 
acids 100-293) and nuclear localization and oligomerization 
domains located in the C-terminal part of p53, that are re-
quired for the assembly of p53 tetramers. Consequently, this 
putative mutant form of p53 cannot activate transcription or 
exert its anti-oncogenic activity against LT antigen. Therefore, 
the proliferation/differentiation balance is not under the con-
trol of the tumor-suppressor gene p53 in Caco-2 cells, suggest-
ing that the wild-type p53 protein is not necessary for the 
expression of the enterocyte phenotype. Several authors 
have proposed that alterations in p53 gene expression are 
associated with various cancers, such as those of the colon. 
Allelic deletion and p53 point mutation or protein accumula-
tion rarely occur in preneoplastic lesions such as aberrant 
crypt foci of the colon or adenomatous colonic mucosa [1]. 
This finding supports the hypothesis that p53 gene mutation 
or overexpression contributes to progression of colorectal car-
cinoma and is associated with short survival [33]. In contrast, 
p53 point mutations are found in the earliest recognized dys-
plastic lesions emerging from ulcerative colitis [34]. Recent 
data suggest that p53 controls cell cycle arrest at the Gl/S 
transition in response to DNA damage [35], implicating p53 
in negative regulation of cell proliferation. In this connection, 
our results provide evidence that Caco-2 cells are regulated by 
autocrine/intracrine mitogenic factors since parental and 
SV40 LT-transfected cell lines are growing in serum- and glu-
tamine-free conditions. In the gut, glutamine functions as an 
essential nutrient maintaining intestinal structure, prolifera-
tion responses to growth factors such as EGF, and regulating 
expression of differentiation and adhesion markers in intesti-
nal epithelial cells in culture [21-23]. Previous studies also 
indicated that human colon tumors and their derived cell lines 
express a variety of peptide growth factors including EGF, 
TGF-oc, amphiregulin, IGFs, bFGF, and gastrin, which may 
regulate cell mitogenesis and growth at the autocrine level 
[36^t0]. For example, the conditioned medium from Caco-2 
cell cultures contained approximately 5-15 ng/ml immuno-
reactive IGF-II after 24 h of culture [41]. This IGF-II concen-
tration produced half-maximal displacement of [125I]IGF-II 
binding in the same system. 
Secondly, the absence of functional p53 in Caco-2 cells is 
associated with high expression of the RBI transcripts and 
abundance of the Rbl/Rb2 proteins in both parental and 
transfected cells. This may account for the negative effects 
of the p53 protein on RBI gene promoter activity, as previ-
ously evidenced in other systems [42,43]. High levels of pRbl-
LT-p53 complex are also observed in SV40-transfected cells 
[44], suggesting that this trimolecular assembly may play spe-
cific roles in the transformation process induced by the viral 
oncogene. Cooperation between p53 and pRbl in the control 
of apoptosis and predisposition to malignancy has been pro-
posed from RBI +/—, p53 — /— transgenic mice [45]. In con-
trast, normal human colonic crypts accumulated low levels of 
unphosphorylated Rbl protein that is active in growth sup-
pression and is a feature of the Gl phase of the cell cycle. 
At the molecular level, the SV40LT antigen was found in 
the pRbl or Rb2 immunoprecipitates that we prepared from 
Caco-2 LT9 cells, resulting in the accumulation and persis-
tence of hyperphosphorylated forms of pRbl in post-conflu-
ent cells. The interactions between pRbl and the SV40LT 
antigen involves the 'Rb pocket' that can bind El A of adeno-
virus and human papillomavirus type 16 E7 proteins [46]. Be-
sides binding these viral oncoproteins, the hypophosphory-
lated forms of pRbl also bind and allow the sequestration 
of the cellular protein E2F. The transcription factor E2F 
up-regulates the expression of proteins known to participate 
in cell growth regulation, such as myc, dihydrofolate reduc-
tase and EGF receptors [47]. Accordingly, hypophosphory-
lated pRbl is almost completely absent in exponentially grow-
ing cells. After the acquisition of confluence and terminal 
differentiation, the three hyperphosphorylated forms of 
pRbl are progressively converted into hypophosphorylated 
pRbl. This conversion is associated with down-regulation of 
the c-myc gene in parental and transfected Caco-2 LT9 cells 
(data not shown), and no further increase in cell number in 10 
days post-confluent Caco-2 monolayers. The tumor-suppres-
sors pRbl and Rb2 may therefore contribute to the genetic 
and molecular alterations observed during the neoplastic pro-
gression of human colonic mucosa. Further analysis of Caco-2 
cells expressing variable levels of p53 and pRbl/Rb2 by con-
stitutive or inducible expression of the corresponding sense or 
antisense transcripts will be useful to evaluate the specific 
roles of these proteins in the proliferation and differentiation 
of human enterocytes. 
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